MECLIZINE HYDROCHLORIDE tablet

Country: Bandaríkin

Tungumál: enska

Heimild: NLM (National Library of Medicine)

Virkt innihaldsefni:

MECLIZINE HYDROCHLORIDE (UNII: HDP7W44CIO) (MECLIZINE - UNII:3L5TQ84570)

Fáanlegur frá:

Zydus Lifesciences Limited

Stjórnsýsluleið:

ORAL

Gerð lyfseðils:

PRESCRIPTION DRUG

Ábendingar:

Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride tablets are contraindicated in patients with a hypersensitivity to meclizine or any of the inactive ingredients [see Adverse Reactions (6) and Description (11)]. Risk Summary Data from epidemiological studies have not generally indicated a drug-associated risk of major birth defects with meclizine during pregnancy. However, in a published study, an increased incidence of fetal malformations was observed following oral administration of meclizine to pregnant rats during the period of organogenesis, at doses similar to those used clinically. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Data Human Data Epidemiological

Vörulýsing:

Meclizine Hydrochloride Tablets USP, 12.5 mg are light blue to blue colored, spotted, oval shaped, biconvex uncoated tablet, debossed with '1161' on one side and plain on the other side and are supplied as follows: NDC 70771-1539-3 in bottles of 30 tablets with child-resistance closure NDC 70771-1539-9 in bottles of 90 tablets with child-resistance closure NDC 70771-1539-1 in bottles of 100 tablets with child-resistance closure NDC 70771-1539-0 in bottles of 1000 tablets with non-child-resistance closure NDC 70771-1539-4 in unit-dose blister cartons of 100 tablets (10 X 10 Unit-dose) Meclizine Hydrochloride Tablets USP, 25 mg are light yellow to yellow colored, spotted, oval shaped, biconvex uncoated tablets debossed with '1162' on one side and plain on the other side and are supplied as follows: NDC 70771-1540-3 in bottles of 30 tablets with child-resistance closure NDC 70771-1540-9 in bottles of 90 tablets with child-resistance closure NDC 70771-1540-1 in bottles of 100 tablets with child-resistance closure NDC 70771-1540-0 in bottles of 1000 tablets with non-child-resistance closure NDC 70771-1540-4 in unit-dose blister cartons of 100 tablets (10 X 10 Unit-dose) Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container (USP).

Leyfisstaða:

Abbreviated New Drug Application

Vara einkenni

MECLIZINE HYDROCHLORIDE- MECLIZINE HYDROCHLORIDE TABLET
ZYDUS LIFESCIENCES LIMITED
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
MECLIZINE
HYDROCHLORIDE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING
INFORMATION FOR
MECLIZINE HYDROCHLORIDE TABLETS.
MECLIZINE HYDROCHLORIDE TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1957
INDICATIONS AND USAGE
Meclizine hydrochloride tablets are indicated for the treatment of
vertigo associated with diseases
affecting the vestibular system in adults (1). (1)
DOSAGE AND ADMINISTRATION
Recommended dosage: 25 mg to 100 mg daily, in divided doses (2.1).
Tablets: Swallow whole (2.2).
DOSAGE FORMS AND STRENGTHS
Tablets: 12.5 mg, and 25 mg (3).
CONTRAINDICATIONS
Meclizine hydrochloride tablets are contraindicated in patients with
hypersensitivity to meclizine or any of
the inactive ingredients (4). (4)
WARNINGS AND PRECAUTIONS
May cause drowsiness: Use caution when driving a car or operating
dangerous machinery (5.1).
Potential anticholinergic action: this drug should be prescribed with
care to patients with a history of
asthma, glaucoma, or enlargement of the prostate gland (5.2).
ADVERSE REACTIONS
Common adverse reactions are anaphylactic reaction, drowsiness, dry
mouth, headache, fatigue, and
vomiting. On rare occasions blurred vision has been reported (6). (6)
TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT ZYDUS PHARMACEUTICALS
(USA) INC. AT 1-
877-993-8779 OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH. (6)
DRUG INTERACTIONS
Coadministration of meclizine hydrochloridewith other CNS depressants,
including alcohol, may result
in increased CNS depression (7.1).
CYP2D6 inhibitors: As meclizine is metabolized by CYP2D6, there is a
potential for drug-drug
interactions between meclizine hydrochlorideand CYP2D6 inhibitors
(7.2).
SEE 17 FOR PATIENT COUNSELING INFORMATION.
REVISED: 8/2023
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosage
2.2 Administrat